Imagine you are developing antibodies—drugs precisely aimed at a target, for example a viral protein or onco-marker. You test a series of antibodies and find that some work, while others do not.

Recently, the team led by Professor Wang Mengdi at Princeton University proposed a “Trajectory-Aware RL” framework—TraceRL in ...